Managed Care Challenges and Solutions for PDT Coverage, and Evaluating Patient Outcomes and Satisfaction

Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.

In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for patients with hereditary angioedema.

A single-center retrospective study found the approval and use of new agents to treat chronic graft-versus-host disease (GVHD) is associated with quality-of-life improvements.

Chronic and acute graft-versus-host disease are managed differently, affect different organs, and impact patients in different ways.

Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.

Arwen Podesta, M.D., discussed prescription digital therapeutics for people with mental health and substance abuse conditions in a Managed Healthcare Executive K-Cast video series. Podesta is a New Orleans-based board-certified adult psychiatrist with subspecializations in addiction medicine, forensic psychiatry and integrative medicine.